Citigroup
VVOS icon

Citigroup’s Vivos Therapeutics VVOS Stock Holding History

Citigroup’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Hold
1
– – ﹤0.01% 5877
2025
Q4 		$2 Hold
1
– – ﹤0.01% 5946
2025
Q3 		$3 Buy
+1
New +$5 ﹤0.01% 6011

Other funds holding VVOS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citigroup's VVOS Position: Q1 2026 in Review

Citigroup held its Vivos Therapeutics (VVOS) position steady in Q1 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #5877.

Citigroup first reported a position in VVOS in Q3 2025 and has held it in 3 quarters since. The position peaked at $3 in Q3 2025. 24 funds tracked by Wall St. Rank hold VVOS as of Q1 2026.

  • Citigroup held 1 share of Vivos Therapeutics worth $1 as of Q1 2026.
  • Citigroup left its Vivos Therapeutics share count unchanged in Q1 2026.
  • Vivos Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5877 holding.
  • Citigroup first reported a position in Vivos Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Citigroup's Vivos Therapeutics position peaked at $3 in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.